Liposome News and Research RSS Feed - Liposome News and Research

A liposome is a very tiny, fat-like particle that is made in the laboratory. In medicine, liposomes containing drugs or other substances are used in the treatment of cancer and other diseases. Drugs given in liposomes may have fewer side effects and work better than the same drugs given alone.
Encapsula releases 2 new liposome based products

Encapsula releases 2 new liposome based products

Encapsula NanoSciences announces the release of two new liposome ­based products; Curcusome® and Taurosome™. Curcusome® or liposomal curcumin is a nutraceutical supplement that comes innovatively packaged in a powder ­release cap for consumer ease. [More]
Scientists use femtosecond lasers to tackle Parkinson's disease

Scientists use femtosecond lasers to tackle Parkinson's disease

Scientists are combining physics and neurobiology to tackle Parkinson's disease. The Okinawa Institute of Science and Technology Graduate University's Femtosecond Spectroscopy Unit and Neurobiology Research Unit, along with collaborators at the University of Otago, New Zealand are using lasers, nanotechnology and neuroscience to develop a new, versatile drug delivery system. [More]
Aradigm begins Pulmaquin Phase III study for treatment of non-CF BE

Aradigm begins Pulmaquin Phase III study for treatment of non-CF BE

Aradigm Corporation ("Aradigm" or the "Company") today announced the dosing of the first patient in the ORBIT-4 (Once-daily Respiratory Bronchiectasis Inhalation Treatment) Phase III pivotal clinical trial of Aradigm's proprietary formulation of inhaled ciprofloxacin (Pulmaquin®) for the treatment of non-cystic fibrosis bronchiectasis (non-CF BE). [More]
Celsion acquires all assets of EGEN

Celsion acquires all assets of EGEN

Celsion Corporation, an oncology drug development company, today announced the completion of the acquisition by Celsion of substantially all of the assets of EGEN, Inc., a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases. [More]
Enhancing vaccine efficiency through encapsulation

Enhancing vaccine efficiency through encapsulation

A work published in Vaccine, and led by the Institut de Biotecnologia i de Biomedicina (IBB – UAB) and ICN2, studies the biodistribution and immunological efficacy protecting from infection of immunostimulant-loaded nanoliposomes in zebrafish in vivo. [More]
Celsion signs definitive asset purchase agreement to acquire EGEN

Celsion signs definitive asset purchase agreement to acquire EGEN

Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, today announced the signing of a definitive asset purchase agreement in which Celsion will acquire substantially all of the assets of EGEN, including its Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas™ for delivery of DNA and mRNA, TheraSilence™ for delivery of RNA, and RAST™ for Cell Enabled Expression and Secretion of RNA. [More]
Aradigm’s common shares approved for listing on NASDAQ Capital Market

Aradigm’s common shares approved for listing on NASDAQ Capital Market

Aradigm Corporation is pleased to announce that its common shares have been approved for listing on the NASDAQ Capital Market. [More]

3D capillary device can increase production of high-quality liposomes

When the English author Sir Francis Bacon wrote "The world's a bubble" in 1629, it's a safe bet he wasn't thinking about microfluidics. [More]
Aradigm receives QIDP designation for its inhaled antibiotic candidate, Pulmaquin

Aradigm receives QIDP designation for its inhaled antibiotic candidate, Pulmaquin

Aradigm Corporation (the "Company") today announced that the U.S. Food and Drug Administration (FDA) has designated the Company's lead inhaled antibiotic candidate, Pulmaquin®, as a Qualified Infectious Disease Product (QIDP). [More]
Bio-Path Holdings reports net loss of $504,876 for first quarter 2014

Bio-Path Holdings reports net loss of $504,876 for first quarter 2014

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced operational and financial results for the first quarter ended March 31, 2014. [More]
Anti-cancer drug delivery method smuggles drug into cancer cell before triggering release

Anti-cancer drug delivery method smuggles drug into cancer cell before triggering release

Biomedical engineering researchers have developed an anti-cancer drug delivery method that essentially smuggles the drug into a cancer cell before triggering its release. [More]
Captisol-enabled Melphalan meets primary end points in phase 2 pivotal trial

Captisol-enabled Melphalan meets primary end points in phase 2 pivotal trial

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that its pivotal trial of Captisol-enabled (propylene glycol-free) Melphalan met its primary end points. [More]

FDA approves additional manufacturing suite for Pacira’s EXPAREL

Pacira Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration approved an additional bulk manufacturing suite, referred to as Suite C, for EXPAREL (bupivacaine liposome injectable suspension). The suite is housed at the company's Science Center Campus in San Diego, where EXPAREL is currently manufactured. [More]
Insmed reports results from ARIKAYCE phase 2 trial for treatment resistant NTM lung infections

Insmed reports results from ARIKAYCE phase 2 trial for treatment resistant NTM lung infections

Insmed Incorporated today reported results from the Company's phase 2 clinical trial of ARIKAYCETM, or liposomal amikacin for inhalation, for the treatment of patients with treatment resistant nontuberculous mycobacterial (NTM) lung infections. [More]
AJT describes novel approach to long-term tolerance in organ transplantation

AJT describes novel approach to long-term tolerance in organ transplantation

REGiMMUNE Corporation announced that the American Journal of Transplantation (AJT) has published its paper that describes a novel approach to long-term tolerance in organ transplantation with continuous administration of immune suppressants. [More]

Pacira Pharmaceuticals initiates Phase 3 clinical trial of EXPAREL in femoral nerve block

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the Phase 3 clinical trial assessing the safety and efficacy of EXPAREL® (bupivacaine liposome injectable suspension) in femoral nerve block for total knee arthroplasty met its primary efficacy endpoint. [More]
Cancer cells less likely to develop resistance when multiple drugs delivered simultaneously

Cancer cells less likely to develop resistance when multiple drugs delivered simultaneously

Researchers have developed a technique for creating nanoparticles that carry two different cancer-killing drugs into the body and deliver those drugs to separate parts of the cancer cell where they will be most effective. The technique was developed by researchers at North Carolina State University and the University of North Carolina at Chapel Hill. [More]
Pronai Therapeutics reports positive results from PNT2258 Phase II study on lymphoma

Pronai Therapeutics reports positive results from PNT2258 Phase II study on lymphoma

ProNAi Therapeutics, Inc., a leader in developing nucleic acid therapeutics, presented safety and efficacy data from its ongoing Phase II study yesterday at the 55th Annual Meeting of the American Society for Hematology (ASH) in New Orleans, Louisiana. [More]
Duke University receives $2.9M grant to develop HIV vaccine candidate

Duke University receives $2.9M grant to develop HIV vaccine candidate

Duke University has received a grant of up to $2.9 million from the Bill & Melinda Gates Foundation to produce an HIV vaccine candidate that will be tested in humans. [More]
Pharmalink's Busulipo receives FDA orphan drug designation

Pharmalink's Busulipo receives FDA orphan drug designation

Pharmalink AB, a specialty pharma company focused on orphan and niche products, today announces its product Busulipo, a best-in-class conditioning agent for use in cancer patients prior to hematopoietic stem cell transplantation (HSCT; also known as bone marrow transplantation), has received orphan drug designation from the US Food and Drug Administration. [More]